Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Currently, there is an ongoing randomised double-masked placebo-controlled trial, the SUMMIT trial, studying the efficacy and safety of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and GLP-1 receptors, versus placebo in HFpEF patients with obesity (NCT04847557)
KEY FEATURES Designed for advanced biochemical and regenerative pathway research: Product name: BPC-157 (Body Protection Compound-157) Specifications: BC2, BC5, BC10 Content: 2mg / 5mg / 10mg 10 vials Purity: 98% (HPLC verified) Analytical validation: LC-MS confirmed Structurally stable 15-amino acid peptide High aqueous solubility Excellent stability in lyophilized form Manufactured under controlled laboratory conditions PRODUCT OVERVIEW BPC-157 is a pentadecapeptide (15 amino acids) originally derived from a protective protein found in gastric juice
five trials
If injected in high doses, it can put stress on the kidneys or lead to toxic buildup in the body, leading to serious health concerns and even death
Barnard R, Haynes KM, Werther GA, Waters MJ
Q: Will I lose muscle on this stack
US$ 23.08
US$ 22.94
